The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
|Podcasts|March 27, 2019
Gaining Insight Into Progress Made With Genitourinary Cancers in Pasadena
Author(s)Onclive Team
We traveled to Pasadena, California, for a State of the Science Summit™ on Genitourinary Malignancies, which focused on the rapidly evolving landscapes of kidney, bladder, and prostate cancer.
Advertisement
We recently traveled to Pasadena, California, for a State of the Science Summit™ on Genitourinary Malignancies. At the meeting, faculty from City of Hope, Huntsman Cancer Center, and the University of Washington discussed the rapidly evolving landscapes of kidney, bladder, and prostate cancer.
Advertisement
Related to this article
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.
The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.
UCSF experts will present key research at the 31st Society for Neuro-Oncology Annual Meeting.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
2
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
5